Replies to post #92890 on Biotech Values

[DewDiligence]

So, after careful consideration, the FDA accepted the Copaxone application from NVS/MNTA for review even though the FDA knew from the start that an ANDA was an inappropriate regulatory pathway for this application? You’re still not making any sense, IMHO.